Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01812213 · ClinicalTrials.gov registry record · Phase 2
Beta-Amyloid Imaging With [18F]NAV4694 PET in Predicting Progression to AD in Subjects MCI
A Phase 2 study, sponsored by Navidea Biopharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
NCT01812213 is a Phase 2 study that was terminated before completion, run by Navidea Biopharmaceuticals. The registered enrollment target is 76 participants.
The verdict
NCT01812213, a Phase 2 study, was terminated before completion, sponsored by Navidea Biopharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
Study Summary
To investigate whether \[18F\]NAV4694 positron emission tomography (PET) scan findings have the ability to distinguish subjects with mild cognitive impairment (MCI) who progress to Alzheimer's disease (AD) from those who do not.
Interventions
- DRUG [18F]NAV4694
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2013-03 |
| Est. Completion | 2017-11-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01812213
The ClinicalTrials.gov registry entry for NCT01812213 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Navidea Biopharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [18F]NAV4694 is the first listed.
NCT01812213 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01812213 about?
NCT01812213 is a clinical study titled "Beta-Amyloid Imaging With [18F]NAV4694 PET in Predicting Progression to AD in Subjects MCI". To investigate whether \[18F\]NAV4694 positron emission tomography (PET) scan findings have the ability to distinguish subjects with mild cognitive impairment (MCI) who progress to Alzheimer's disease (AD) from those who do not.
What is the current status of trial NCT01812213?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2013-03. Estimated completion is 2017-11-02.
What interventions are being tested in trial NCT01812213?
The interventions under investigation include: [18F]NAV4694 (DRUG).
Who is sponsoring clinical trial NCT01812213?
This trial is sponsored by Navidea Biopharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.